Thus, although the inhibition of PKC activity by darovasertib significantly inhibits MAPK activity, it did not induce cell death in the majority of uveal melanoma, as PKC inhibition does not inhibit multiple activated Gα pathways downstream of PKC (Robertson et al., 2017). The gene discussed is PRRT2; the disease is uveal melanoma.